Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16794624 | 0.76 | IDO1 (0.31) | IDO1 | |
| SCHEMBL8533579 | 0.74 | IDO1 (0.33) | KMT2AKMODYRK1AIDO1 | |
| SCHEMBL29600612 | 0.64 | PDPK1 (0.46) | ASIC3ALDH1A1KMT2AMKNK1MKNK2 | |
| SCHEMBL1060179 | 0.63 | — | — | |
| Hydrochloric Acid SCHEMBL10688336 | 0.61 | — | — | |
| Hydrochloric Acid SCHEMBL6618909 | 0.61 | — | — | |
| SCHEMBL1702320 | 0.60 | SMN1; SMN2 (0.47) | ALDH1A1KMT2AMKNK1MKNK2MEN1 | |
| SCHEMBL23514354 | 0.59 | — | — | |
| SCHEMBL64373 | 0.59 | — | — | |
| SCHEMBL17293092 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858993-B1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2018-01-10 | — | — | EP | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| EP-2714692-B1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-20170029441-A1 | AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| CN-104487440-A | Amino-substituted imidazopyridazines | BAYER IP GMBH | 2015-04-01 | — | — | CN | disclosed |
| CN-104321326-A | Amino-substituted imidazopyridazines | Bayer Pharma AG | 2015-01-28 | — | — | CN | disclosed |
| CN-104114559-A | Amino-substituted imidazopyridazines | BAYER IP GMBH | 2014-10-22 | — | — | CN | disclosed |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| EP-2714692-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2014-04-09 | — | — | EP | disclosed |
| CN-103717604-A | Substituted aminoimidazopyridazines | BAYER IP GMBH | 2014-04-09 | — | — | CN | disclosed |
| EP-2710004-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-03-26 | — | — | EP | disclosed |
| EP-2710004-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-03-26 | — | — | EP | disclosed |
| CN-103687858-A | Amino-substituted imidazopyridazines as MKNK1 kinase inhibitors | BAYER IP GMBH | 2014-03-26 | — | — | CN | disclosed |
| WO-2012163942-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012163942-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012156367-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012156367-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029441-A1 | AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS | VEGFA, PGF, FLT1 | ASIC3 4692/4885ALDH1A1 1490/4885KMT2A 2669/4885 |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | CCND2, CCND1, VEGFA | ASIC3 4765/4885ALDH1A1 316/4885KMT2A 1685/4885 |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | MKNK1, MKNK2, MAP4K5 | ASIC3 3953/4885ALDH1A1 2220/4885KMT2A 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.